Radiopharmaceutical developer Navidea Biopharmaceuticals plans to collaborate with the University of Alabama at Birmingham on a clinical study to evaluate a radiolabeled, humanized monoclonal antibody.
The antibody is part of Navidea's radioimmuno-guided surgery (RIGS) monoclonal antibody targeting technology, according to the firm. The RIGS technology may be useful prior to, during, or after surgery to identify cancerous tissue undetectable by traditional diagnostic and intraoperative techniques, according to Navidea.
The study will include up to 20 patients with colorectal cancer who will receive the RIGS agent and be assessed by SPECT/CT for liver metastasis. It will be funded in part through a Small Business Innovation Research (SBIR) grant Navidea received from the U.S. National Cancer Institute (NCI).
